When you choose superiority for your patients,
Help them save on the cost of their BRILINTA
Download the Savings Card >>Email the Savings Card >>
BRILINTA FOR FIVE
Each month, every month, for as long as you prescribe.
9 out of 10 Commercially insured patients
pay less than the cost of generic clopidogrel with a BRILINTA Savings Card2*†ǂ
BRILINTA is
more affordable than
you may think1
BRILINTA is
more affordable than
you may think1
The Savings Card lowers the monthly cost of BRILINTA
Commercially insured patients may pay approximately
HALF THE COST
of generic clopidogrel2*†‡
With the BRILINTA Savings Card, patients can:
- Pay as low as $5*† for a 30-day supply
- Save each time they refill
- Maintain the benefit for as long as they're prescribed BRILINTA
Pricing comparisons do not imply comparable efficacy, safety, or FDA-approved indications.
Individual costs and benefit design may vary. Please consult with individual plans for specific information. AstraZeneca does not endorse any individual Commercial, Medicare Part D, or Medicaid plan or plans.
*Eligible patients will pay as low as $5 for a 30-day supply subject to a maximum savings of $200 per 30-day supply. Patients who remain eligible are automatically re-enrolled each year. See eligibility rules and restrictions.
†Subject to eligibility rules; restrictions apply.
‡"Patients" means covered lives (EGWP, Medicare MA, Medicare PDP, Medicare SN, Medi-Medi, PACE) at tiers 1-7 Nationwide as calculated by Fingertip Formulary® 1/21/25.
Help patients save today
Download a Savings Card for your patient
Every download will have a different number so please don't make duplicates of the same card.
Email a Savings Card to your patient
If your patients fill their prescriptions through mail order, they can fill out this form or call 1-888-512-7454.
Please note: If you are a health care professional affiliated with an employer, institution, or committee, or practicing in a state that restricts what items you may receive from manufacturers, we ask that you not accept or download any restricted items from this site. If you are a health care provider practicing in Vermont, we are required by state law to deny you permission to download any items made available on this site.
Do you have questions about BRILINTA?
EXPLORE MORE
STUDY DESIGNS
PLATO STUDY DESIGN
PLATO was a randomized, international, double-blind, controlled comparative study in patients with ACS hospitalized with or without ST-segment elevation, with an onset of symptoms within 24 hours (N=18,624). The study compared BRILINTA (180-mg loading dose, 90 mg twice daily thereafter) to clopidogrel (300-mg to 600-mg loading dose, 75 mg daily thereafter) for the prevention of thrombotic CV events (CV death, MI, or stroke). Study period was 12 months, with median duration of therapy of 277 days. BRILINTA and clopidogrel were studied with aspirin and other standard therapies.3,4
PEGASUS STUDY DESIGN
PEGASUS-TIMI 54 compared BRILINTA (90 mg twice daily or 60 mg twice daily) vs placebo, each given with low-dose aspirin (75 to 150 mg), for the prevention of thrombotic CV events (CV death, MI, or stroke) in 21,162 patients ≥50 years of age with a history of MI (1 to 3 years prior to randomization). Patients also had at least 1 risk factor for thrombotic CV events (age ≥65 years, diabetes mellitus requiring medication, at least 1 other prior MI, evidence of multivessel coronary artery disease, or creatinine clearance <60 mL/min). Only the 60-mg dose strength is approved for use in patients with a history of MI 1 year after an ACS event. Patients were treated for at least 12 months and up to 48 months with a median follow-up time of 33 months.3,5
THEMIS STUDY DESIGN
THEMIS was a randomized, double-blind, placebo-controlled trial of ticagrelor vs placebo in 19,220 patients, on top of low-dose (75 to 150 mg) aspirin for the prevention of thrombotic CV events (CV death, MI, stroke). Patients ≥50 years with type 2 diabetes receiving an anti-hyperglycemic medication for at least 6 months, and with stable CAD (ie, history of PCI, CABG, or angiographic stenosis ≥50% in at least 1 coronary artery) were enrolled. Patients with known prior MI or stroke were excluded. Patients were treated for a median of 33 months and up to 58 months.3,6
THALES STUDY DESIGN
THALES was a randomized, international, double-blind, placebo-controlled, multicenter study to investigate dual antiplatelet therapy with BRILINTA (180-mg loading dose, 90 mg twice daily thereafter) and aspirin vs placebo and aspirin in the prevention of stroke or death in patients with acute ischemic stroke or transient ischemic attack (N=11,016). The primary end point was the first occurrence of the composite of stroke or death at 30 days. In both arms, patients received a loading dose of aspirin 300-325 mg followed by aspirin 75-100 mg once daily. Patients were ≥40 years of age, had mild-to-moderate acute noncardioembolic ischemic stroke (NIHSS score ≤5), or high-risk TIA (ABCD2 score ≥6 or symptomatic intracranial or extracranial arterial stenosis [≥50% narrowing in the diameter of the lumen of an artery that could account for the TIA]). Patients were randomized within 24 hours and treated for a median of 31 days.3,7
REAL-WORLD REGISTRY
An observational real-world comparative effectiveness study evaluated 45,073 consecutive patients with acute MI, discharged on clopidogrel or ticagrelor, using data from the SWEDEHEART Registry between 2010 and 2013. The analysis was adjusted for patient age, sex, pre-existing comorbidities, ACS presentation characteristics, in-hospital course, and discharge medications. This was an observational registry trial and while analyses were adjusted for confounding factors, the results are subject to potential bias and should be interpreted with caution.8
ABCD2=Age, Blood pressure, Clinical features, Duration of TIA, and Diabetes mellitus; ACS=acute coronary syndrome; CABG=coronary artery bypass graft; CAD=coronary artery disease; CV=cardiovascular; MI=myocardial infarction; NIHSS=National Institutes of Health Stroke Scale; PCI=percutaneous coronary intervention; PEGASUS=Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin; PLATO=PLATelet inhibition and patient Outcomes; SWEDEHEART=Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies; THALES=Acute STroke or Transient IscHemic Attack Treated with TicAgreLor and Aspirin for PrEvention of Stroke and Death; THEMIS=Effect of Ticagrelor on Health Outcomes in DiabEtes Mellitus Patients Intervention Study; TIA=transient ischemic attack; TIMI=Thrombolysis in Myocardial Infarction.
References
- Fingertip Formulary®. January 21, 2025.
- Data on File, US-78783, AstraZeneca Pharmaceuticals LP.
- BRILINTA® (ticagrelor) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2024.
- Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057 and Supplementary Appendix.
- Bonaca MP, Bhatt DL, Cohen M, et al; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-1800.
- Steg PG, Bhatt DL, Simon T, et al; THEMIS Steering Committee and Investigators. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381(14):1309-1320.
- Johnston SC, Amarenco P, Denison H, et al; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383(3):207-217 and Supplementary Appendix.
- Sahlén A, Varenhorst C, Lagerqvist B, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016;37(44):3335-3342.
Full Language for Commercially Insured and Cash-Paying Patients
ELIGIBILITY: You may be eligible for this offer if you are insured by commercial insurance and your insurance does not cover the full cost of your prescription, or you are not insured and are responsible for the cost of your prescriptions. Patients who are enrolled in a state- or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, and patients who are Medicare-eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. If you are enrolled in a state- or federally funded prescription insurance program, you may not use this Savings Card even if you elect to be processed as an uninsured (cash-paying) patient. This offer is not insurance and is restricted to residents of the United States and Puerto Rico.
TERMS OF USE: Eligible commercially insured/covered patients with no restrictions (step-edit, prior authorization, or NDC block) and a valid prescription for BRILINTA® (ticagrelor) tablets who present this Savings Card at participating pharmacies will pay as low as $5 per 30-day supply. A $200 maximum savings limit applies; patient’s out-of-pocket expense may vary. If you are insured and your insurance does not cover or has a managed-care restriction on your prescription (step-edit, prior authorization, or NDC block), you will pay as low as $5 per 30-day supply. If you pay cash for your prescription, AstraZeneca will pay up to the first $100 per month, and you will be responsible for any remaining balance, for each monthly prescription. Other restrictions may apply. Patient is responsible for applicable taxes, if any. Nontransferable, limited to one per person, cannot be combined with any other offer. Void where prohibited by law, taxed, or restricted. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. AstraZeneca reserves the right to rescind, revoke, or amend this offer, eligibility, and terms of use at any time without notice. This offer is not conditioned on any past, present, or future purchase, including refills. Offer must be presented along with a valid prescription at the time of purchase. For additional details about this offer, please visit www.brilinta.com. If you have any questions regarding this offer, please call 1-833-274-5468.
BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.
Pharmacist Instructions for a Patient With an Eligible Third-Party Payer:
For Commercially Insured/Covered Patients: Submit the claim to the primary Third-Party Payer first, then submit the balance due to Change Healthcare as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 8. This will reduce the eligible patient’s out-of-pocket costs to as low as $5 for each 30-day supply, subject to a maximum savings limit of $200 for the program; patient’s out-of-pocket expenses may vary. Reimbursement will be received from Change Healthcare.
Pharmacist Instructions for Insured/Not Covered Patients: Submit the claim to the primary Third-Party Payer first; if the primary claim submission shows a managed-care restriction (step-edit, prior authorization, or NDC block), continue the claim adjudication process and submit the balance due to Change Healthcare as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 3. This will reduce eligible patient’s out-of-pocket costs to as low as $5 for each 30-day supply, subject to a maximum savings limit for the program; patient’s out-of-pocket expenses may vary. Reimbursement will be received from Change Healthcare.
Pharmacist Instructions for a Cash-Paying Patient: Submit this claim to Change Healthcare. A valid Other Coverage Code (eg, 1) is required. The card may cover up to a maximum of $100 per each 30-day supply. Reimbursement will be received from Change Healthcare. For any questions regarding Change Healthcare online processing, please call the Help Desk at 1-800-422-5604.
Program managed by ConnectiveRx on behalf of AstraZeneca. 